Dusheiko G M, Zuckerman A J
University Department of Medicine, Royal Free Hospital and School of Medicine, London, UK.
J Antimicrob Chemother. 1993 Jul;32 Suppl A:107-20. doi: 10.1093/jac/32.suppl_a.107.
A substantial number of anti-viral compounds have been evaluated for the treatment of patients with chronic viral hepatitis. A few of these compounds have now achieved clinical applicability. alpha-Interferon is the most widely studied and remains the main treatment for chronic hepatitis B and C. Unfortunately in both these conditions only a minority of patients respond to interferon therapy, although the response can be complete in some patients. Some parameters have been identified which assist in the selection of patients for treatment. Several other cytokines, including thymosin, have been evaluated for the treatment of chronic hepatitis B. There are a number of promising new nucleosides which may inhibit hepatitis B virus and their action is being studied. Relapse rates are unknown however with these compounds. Ribavirin, a guanosine analogue, is also efficacious in treating a proportion of patients with chronic hepatitis C and the drug may be useful in treating patients with cirrhosis or patients who have an auto-immune diathesis.
大量抗病毒化合物已被评估用于治疗慢性病毒性肝炎患者。其中一些化合物现已具备临床适用性。α干扰素是研究最为广泛的，并且仍然是慢性乙型和丙型肝炎的主要治疗方法。不幸的是，在这两种情况下，只有少数患者对干扰素治疗有反应，尽管在一些患者中反应可能是完全的。已经确定了一些有助于选择治疗患者的参数。其他几种细胞因子，包括胸腺素，已被评估用于治疗慢性乙型肝炎。有许多有前景的新核苷可能抑制乙型肝炎病毒，并且它们的作用正在研究中。然而，这些化合物的复发率尚不清楚。利巴韦林，一种鸟苷类似物，在治疗一部分慢性丙型肝炎患者中也有效，并且该药物可能对治疗肝硬化患者或有自身免疫素质的患者有用。
